Core Points - Zealand Pharma A/S will host a conference call on November 13, 2025, at 2:00 pm CET (8:00 am ET) to present its third quarter 2025 financial results [1] - The call will feature key executives including President and CEO Adam Steensberg, CFO Henriette Wennicke, and CMO David Kendall, followed by a Q&A session [2] - Participants can register for the call and access the live audio webcast through provided links, with a recording available post-event on the company's website [3] Company Overview - Zealand Pharma A/S is a biotechnology company focused on the discovery and development of innovative peptide-based medicines, with over 10 drug candidates in clinical development, including two that have reached the market and three in late-stage development [4] - The company has established development and commercial partnerships with various pharmaceutical companies for its marketed products [4] - Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma also has a presence in the U.S. [5]

Core Insights - The U.S. FDA has granted Orphan Drug Designation (ODD) to Minovia Therapeutics' lead investigational compound, MNV-201, for Myelodysplastic Syndrome (MDS), adding to its existing Fast Track Designation [1][2] - MNV-201 is a first-in-class mitochondrial cell therapy aimed at treating mitochondrial diseases and age-related decline, with a focus on improving outcomes for MDS patients [3][7] - Minovia has entered into a definitive business combination agreement with Launch One Acquisition Corp., with the transaction expected to close in late 2025, leading to a new Nasdaq listing [5] Company Overview - Minovia Therapeutics is a clinical-stage biotechnology company based in Haifa, Israel, focused on developing therapies to replace defective mitochondria and combat aging [8][9] - The company is currently conducting a Phase Ib study of MNV-201 in low-risk MDS patients, with six out of nine expected patients already dosed [6] Product Details - MNV-201 utilizes Minovia's proprietary Mitochondrial Augmentation Technology (MAT) to enhance patients' stem cells with healthy mitochondria, aiming to restore organ function [7] - Early-stage clinical studies of MNV-201 have shown a strong safety profile and potential multi-system benefits for patients with Pearson Syndrome [7]

Core Viewpoint - MediWound Ltd. is set to report its financial results for Q1 2025 on May 21, 2025, and will host a conference call to discuss these results and provide corporate updates [1][2]. Company Overview - MediWound Ltd. is a global biotechnology company specializing in enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved product, NexoBrid, is used for the enzymatic removal of eschar in thermal burns and is marketed in multiple regions including the U.S., EU, and Japan [3]. - The company is also developing EscharEx, a late-stage investigational therapy aimed at chronic wound debridement, which has shown clinical advantages over existing products and targets a significant global market opportunity [3]. Conference Call Details - The conference call and live webcast will take place at 8:30 a.m. Eastern Time on May 21, 2025. Participants can join via various dial-in numbers provided for toll-free, Israel, and international calls [2]. - An archived version of the webcast will be available for replay on the Investors section of the MediWound website [2]. Contact Information - MediWound has provided contact details for its Chief Financial Officer and Managing Director, as well as media contacts for further inquiries [5].